Safety and Efficacy of Deferasirox (ICL670) in Patients With Iron Overload Resulting From Hereditary Hemochromatosis

NCT00395629 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

49

Enrollment

INDUSTRY

Sponsor class

Conditions

Iron Overload
Hereditary Hemochromatosis

Interventions

DRUG: Deferasirox (ICL670)

Sponsor

Novartis Pharmaceuticals